People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Other, Software / Tech, Other Technology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Delphinus Medical Technologies, Inc. | — | Biotechnology | Series B | $117.9M | $221.5M | 2017 |
| Aurcana Corp | — | Other | Series C | $101.5M | $7.6M | 2020 |
| Intouch Technologies Inc | — | Software / Tech | Series B | $63.5M | $639.6M | 2012 |
| Genomenon, Inc. | — | Biotechnology | Series B | $28.8M | $41.8M | 2022 |
| gloStream, Inc. | — | Other Technology | Series A | $17.8M | $34.3M | 2009 |
| Molecular Imaging, Inc. | — | Biotechnology | Series A | $12.0M | $55.5M | 2013 |
| Micro-LAM, Inc. | — | Other Technology | Series A | $11.6M | $35.4M | 2019 |
| dScout, Inc. | — | Other Technology | Series A | $11.0M | $208.0M | 2018 |
| Intervention Insights, Inc. | — | Other Health Care | Series A | $6.4M | $84.0M | 2017 |
Michael Gross at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Gross on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patricia Glaza | 2 | 3 |
| Michael Klein | 1 | 9 |
| Wright Steenrod | 1 | 9 |
| Scott White | 1 | 7 |
| Paul McCreadie | 1 | 6 |
| Stephen Sullivan | 1 | 6 |
| Peter Shagory | 1 | 5 |
| John Kerschen | 1 | 5 |
| Charles Moret | 1 | 4 |
| Mark Olesnavage | 1 | 4 |
| David Fry | 1 | 4 |
| RONALD K NETOLITZKY | 1 | 4 |
| Nicole Walker | 1 | 4 |
| Timothy Parker | 1 | 3 |
| David Jahns | 1 | 3 |
| Clynt Taylor | 1 | 3 |
| Michael Chan | 1 | 3 |
| Gerald Callahan | 1 | 3 |
| John Neis | 1 | 3 |
| Jeffrey Bocan | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.